Propanc Biopharma, Inc. (PPCB) company profile
Close on Nov 12, 2026Market cap $12.16MP/E –Yield –
About Propanc Biopharma
Pharmaceutical Preparations, SIC 2834
The text does not contain factual narrative descriptions explaining what the company does, its main products or services, operating segments, or customers. The provided content consists exclusively of XBRL tags, member classifications, agreement references, and date ranges without any contextual business descriptions or operational disclosures.
Additionally, the excerpt provides no factual information concerning the company's scale, facilities, store counts, operating reach, or corporate headquarters. Although tags mention geographic identifiers for the United States and Australia, no narrative or factual statements in the text specify where the company conducts operations or where its headquarters are located.
Summary of the business section of Propanc Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Propanc Biopharma, Inc.
- Headquarters
- Camberwell, Victoria, C3
- Address
- 302/6 Butler Street 3124
- Phone
- 61-03-9882-0780
- Website
- propanc.com
- Employees
- 2, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- SALBERG & COMPANY, P.A, Boca Raton, Florida
Stock & identifiers
- Ticker
- PPCB
- Former tickers
- PPCH until Sep 28, 2017
- Exchange
- Nasdaq
- IPO date
- Jan 7, 2013
- Shares outstanding
- 6M, Sep 23, 2026
- Public float
- $2.66M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, May 18, 2026; 1-for-59983 reverse, Feb 14, 2025; 1-for-2 reverse, Jan 29, 2025; 1-for-1000 reverse, Nov 19, 2020; 1-for-500 reverse, Jun 24, 2019; 1-for-250 reverse, Apr 20, 2017
- SEC CIK
- 1517681
- CUSIP
- 74346N800
- ISIN
- US74346N8002
- FIGI
- BBG002086386
- Share class FIGI
- BBG002086411
- LEI
- 549300Q3HY827FNV8Y56
- EIN
- 33-0662986
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Propanc Biopharma's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had two full-time and employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?